IMRX vs INDP

Immuneering Corporation vs Indaptus Therapeutics, Inc. — Valuation Comparison 2026

IMRX

Pharmaceutical Preparations
Immuneering Corporation
Quality
4.5
out of 10
Value Trap
26
LOW
Price
$5.77
Last close
Models
7/13
Active
VS

INDP

Pharmaceutical Preparations
Indaptus Therapeutics, Inc.
Quality
2.5
out of 10
Value Trap
36
LOW
Price
$1.76
Last close
Models
4/13
Active

Model-by-Model Comparison

ModelType IMRX Fair ValueIMRX Upside INDP Fair ValueINDP Upside
Bayesian DCF Intrinsic $1.71 -70.4% $0.05 -97.1%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $1.67 -71.1% $0.21 -90.3%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for IMRX vs INDP — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

IMRX vs INDP — Which Stock Is More Undervalued?

IMRX scores higher with a 4.5/10 quality rating vs INDP's 2.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Immuneering Corporation (IMRX) and Indaptus Therapeutics, Inc. (INDP) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

IMRX currently trades at $5.77 with a QOC of 4.5/10, while INDP trades at $1.76 with a QOC of 2.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).